Category: 3. Business

  • A tale of 2 workplace models

    A tale of 2 workplace models

    American households have become dependent on Amazon.

    The numbers say it all: In 2024, 83% of U.S. households received deliveries from Amazon, representing over 1 million packages delivered each day and 9 billion individual items delivered same-day or next-day every year. In remarkably short order, the company has transformed from an online bookseller into a juggernaut that has reshaped retailing. But its impact isn’t limited to how we shop.

    Behind that endless stream of packages are more than a million people working in Amazon fulfillment centers and delivery vehicles. Through its growing dominance in retail, Amazon has eclipsed its two major competitors in the delivery business, UPS and FedEx, in terms of package volume.

    What is life like for those workers? Between Amazon’s rosy public relations on the one hand and reporters’ and advocates’ troubling exposés on the other, it can be hard to tell. Part of the reason is that researchers like us don’t have much reliable data: Workers’ experiences at companies such as Amazon, UPS and FedEx can be a black box. Amazon’s arm’s-length relationship with the drivers it depends on for deliveries makes finding answers even harder.

    But that didn’t stop us. Using unique data from the Shift Project, our new study, co-authored with Julie Su and Kevin Bruey, offers the first direct, large-scale comparison of working conditions for drivers and fulfillment employees at Amazon, UPS and FedEx based on survey responses by more than 9,000 workers.

    What we found was deeply troubling – not only for Amazon drivers but also for the future of work in the delivery industry as a whole.

    2 models, 2 realities

    For nearly a century, driving delivery trucks has been a pathway to the middle class, as epitomized by unionized jobs at UPS. UPS drivers, who have been members of the Teamsters union for decades, are employees with legal protections and a collective-bargaining contract.

    In contrast, Amazon has embraced a very different model. Most important is that Amazon does not directly employ nearly any of its delivery drivers.

    Instead, its transportation division, Amazon Logistics, relies on two methods to deliver most of its shipments: Amazon Flex, a platform-like system that treats drivers like independent contractors, and Amazon DSP, a franchise-like system that uses subcontractors. DSP subcontractors are almost all nonunion, and the company has cut ties with DSP contractors whose drivers have attempted to unionize. These practices place downward pressure on the wages and working conditions of drivers throughout the industry.

    The impact on workers is stark.

    Delivery workers at Amazon receive significantly lower wages than at UPS and FedEx, we found. Wage gaps are especially large between the delivery workers at Amazon, who earn US$19 an hour on average, and the unionized drivers at UPS, who make $35.

    We also found that unionized UPS drivers have a clear pathway to upward mobility, while Amazon drivers don’t. At UPS, wages increase sharply the longer a worker has been on the job. Pay starts at $21 an hour, reaching nearly $40 an hour for drivers who’ve been with the company for at least 10 years – which is more than half of them.

    At Amazon, wages start at $17 an hour and don’t increase with tenure. Nearly half of workers have less than a year on the job.


    Source: Amazon Drives Low Wages: The Unraveling of Workplace Protections for Delivery Drivers

    Between lower wages, more unstable schedules, fewer benefits and limited protections from employment laws, Amazon drivers struggle to make ends meet. More than 1 in 4 told us they had gone hungry because they couldn’t afford enough to eat within the past month, and 33% said they couldn’t cover their utility bills. Compared to drivers at UPS and FedEx, Amazon drivers face significant financial instability.

    On top of that, Amazon drivers face intense workplace surveillance and speed tracking – as do workers at the company’s fulfillment centers. Sixty percent of both types of Amazon workers received frequent feedback on the speed of their work from a technological device, and more than two-thirds said that Amazon monitors the quality of their work using technology. That degree of technological surveillance and tracking far outpaces what UPS and FedEx workers told us they were exposed to, representing an extreme case of worker monitoring and performance assessment.

    Using nonemployee drivers contributed to the exponential growth of Amazon as a package delivery company. In 2023, Amazon for the first time delivered more packages than UPS, making it the second-largest parcel carrier in the country – surpassed only by the U.S. Postal Service.

    By building an online retail empire with the capacity to deliver the majority of its own shipments, Amazon’s expansion continues. UPS, by contrast, has seen drops in its revenues, stock value and market capitalization. Amazon’s sheer size and giglike approach are therefore changing industry standards, putting downward pressure on wages, benefits and job stability across the delivery sector.

    The contrast between Amazon and UPS drivers isn’t just about two companies using different models for package delivery – it represents two competing futures for work. As the second-largest retail company and now largest private delivery company in the U.S., Amazon exerts market power that impacts the working conditions of workers beyond its own delivery drivers. Recent reporting indicates that UPS has been experimenting with using gig deliveries, much to the consternation of the union that represents three-quarters of its workforce.

    In the post-World War II era, increasing unionization led to better wages and conditions across much of the economy, including nonunionized sectors. The continuing expansion of Amazon’s business model could signal the unraveling of wages, benefits and protections for working people more generally.

    Continue Reading

  • Fiserv Recognized as a Leader in IDC MarketScape for North America Retail Digital Banking Solutions :: Fiserv, Inc. (FI)

    Fiserv Recognized as a Leader in IDC MarketScape for North America Retail Digital Banking Solutions :: Fiserv, Inc. (FI)





    MILWAUKEE–(BUSINESS WIRE)–
    Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced that it has been named a Leader in the IDC MarketScape: North America Retail Digital Banking Solutions 2025-2026 Vendor Assessment (doc #US52039425, November 2025).

    According to the report, “Experience Digital is suited for banks and credit unions of all sizes, direct banks, and neobanks seeking a core-agnostic digital banking solution deployable across multiple environments. It is especially relevant for existing Fiserv core clients seeking a unified vendor for both core and digital banking, while also offering flexibility for on-premises or cloud-hosted deployment.”

    “We believe being recognized by the IDC MarketScape as a Leader affirms the strength of our strategy and the trust our clients place in us,” said Whitney Russell, Head of Digital and Financial Solutions, Fiserv. “At Fiserv, we are empowering financial institutions to deliver the kind of digital experiences that deepen relationships, drive growth and define the future of banking.”

    The IDC MarketScape provides a rigorous, structured framework for evaluating technology providers, going beyond market share to assess product capabilities, strategic direction, and long-term success potential.

    “As consumers and small businesses increasingly turn to digital banking, Experience Digital enables institutions of all sizes to deliver a full range of sought-after experiences,” said Marc DeCastro, Research Director at IDC. “This positions financial institutions to remain central to real-time money movement, bill pay, P2P, and alerts for the customers they serve.”

    Built to unify consumer and business banking across online and mobile channels, Experience Digital integrates seamlessly with both Fiserv and non-Fiserv core platforms, payments, and merchant services. The platform offers two deployment paths:

    – Configure Digital – for institutions seeking a configurable solution

    – Create Digital – for those building custom experiences with internal development teams

    Experience Digital also connects with:

    – Finxact® – Fiserv’s cloud-native core

    – CashFlow CentralSM – accounts payable/receivable platform

    – Clover® – the world’s smartest point of sale system

    Together, these integrations create a unified digital ecosystem that bridges retail banking, small business services, and payments.

    About IDC MarketScape

    IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

    About Fiserv

    Fiserv, Inc. (NYSE: FI), a Fortune 500 company, moves more than money. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and Clover®, the world’s smartest point-of-sale system and business management platform. Fiserv is a member of the S&P 500® Index, one of TIME Magazine’s Most Influential Companies™ and one of Fortune® World’s Most Admired Companies™. Visit fiserv.com and follow on social media for more information and the latest company news.

    FI-G

    For more information contact:

    Media Relations:

    Mark Jelfs

    Senior Manager, Communications

    Fiserv, Inc.

    +1.262.737.8244

    mark.jelfs@fiserv.com

    Source: Fiserv, Inc.

    Continue Reading

  • £100m wind farm deal to create 300 jobs

    £100m wind farm deal to create 300 jobs

    Catherine MooreBBC News NI

    Belfast Harbour A shot from above of Belfast Harbour. There is water in the middle and land on either side. Two yellow cranes are visible in the distance. There is a cruise ship in the middle of the harbour and a Stena Line ferry on the right. There are also smaller boats.Belfast Harbour

    Wind turbine components will be assembled at Belfast Harbour for two offshore windfarms in the Irish Sea

    A £100m deal which will create about 300 jobs has been agreed between the developers of two Irish Sea offshore wind farms and Belfast Harbour.

    The joint developers of the Mona and Morgan offshore wind farms will lease Belfast Harbour’s D1 terminal for the assembly and preparation of wind turbine components.

    Work is being carried out to get the site ready for use from 2028.

    Joe O’Neill, chief executive of Belfast Harbour, described it as a “huge deal”, not just for the harbour but for Belfast and the wider region.

    “It’s global players coming to Belfast,” he said.

    “We’re delighted we’re able to provide the facilities for them and then the wider region gets the benefits in terms of economic benefits, jobs created and ultimately delivery of clean energy for up to three million homes.”

    He added that Belfast Harbour is the only port on the island of Ireland with offshore wind capabilities.

    Press Eye A man in a blue suit with a blue and yellow patterned tie. He is wearing a white shirt.Press Eye

    Joe O’Neill described it as a “huge deal”, not just for the harbour but for Belfast and the wider region

    The offshore wind farms are two of the biggest planned in the Irish Sea.

    One will be built between Morecambe in north west England and the Isle of Man, while the other will be located off the north Wales coast.

    Once they are operational they could deliver up to 3GW – enough electricity to power around three million UK households.

    The new jobs are expected to involve the marshalling and handling of large wind turbine components and pre-assembly work on turbines and blades.

    On Wednesday, Prime Minister Sir Keir Starmer said the project was helping to “bring about the clean power revolution”, while also creating “skilled, well-paid jobs”.

    He made the comments as he reaffirmed the UK government’s commitment to renewable energy and net zero targets ahead of next week’s Cop30 global summit.

    Clean energy transition

    EnBW, a German energy company, and JERA Nex bp, an offshore wind company based in London, are behind Mona and Morgan.

    JERA Nex bp’s chief executive Nathalie Oosterlinck said the deal was a “direct contribution to the infrastructure needed to drive the energy transition”.

    “This highlights the power of collaboration in driving energy security – the offshore wind industry can not only power millions of homes with clean, homegrown energy but also support job creation and local economic growth.”

    Michael Class, a senior vice president at EnBW, said it was a “milestone commitment”.

    “We are optimistic about fostering a long-lasting partnership between Germany, the UK and Northern Ireland,” he added.

    ‘A fundamental role’

    The harbour reinvests all profits back into the port and the deal will help fund a new £90m dual-purpose cruise and offshore wind site.

    It will also help to pay for works to further reinforce the terminal to handle the next generation of offshore wind turbines, whose components can weigh more than 1,000 tonnes.

    The new terminal will be able to accommodate some of the world’s largest cruise vessels. It will involve a new dual-purpose quay and deep water berth, targeted for completion in 2027.

    Mr O’Neill said the project is both a “boost for clean energy generation” and “positioning [the] cruise business for further growth”.

    “Ports will play a fundamental role in the transition to clean energy particularly for the delivery of offshore windfarms,” he added.

    “There is very limited port capacity to contribute to the transition to offshore wind, clean energy,” Mr O’Neill added.

    “We’re just delighted we’ve through good forethought had the investment in place already to be able to accommodate this project and then hopefully follow on projects.”

    Analysis: Not an investment in renewable power for NI

    Louise CullenBBC News NI’s Agriculture and environment correspondent

    Belfast has a reputation for supporting this sector in manufacturing and engineering terms.

    The investment in the dedicated offshore terminal shows where the Harbour thinks at least some of its future growth is going to come from.

    And they’re right – offshore wind power will be a key element of meeting our Net Zero targets and the industry is experiencing significant growth globally.

    Work is continuing to make offshore wind power part of the future picture, but any plans are at the mercy of the Crown estate which owns the seabed and periodically holds auctions to lease parts of it for such projects.

    But while this investment will bring jobs to Belfast, it is not an investment in renewable power for Northern Ireland.

    Continue Reading

  • Vodafone selects Inter.link to enhance interconnection with other Internet service providers

    Vodafone selects Inter.link to enhance interconnection with other Internet service providers

    Vodafone has chosen Germany-based Inter.link to provide automated, high-quality interconnectivity between its European networks and those of third-party Internet Service Providers (ISPs), content players, and other operators. The move will bolster Vodafone’s existing wholesale business offering a broad range of connectivity and messaging services.

    Inter.link delivers automated, carrier-grade backbone infrastructure at speeds of 100 gigabits per second (Gbps) or 400 Gbps, connecting essential intersections across diverse networks within the broader Internet ecosystem. 1 Gbps typically supports around 1.5 million instant messages.

    Rapidly scale interconnection

    Vodafone will use Inter.link’s automated service, which is available in multiple countries, including 30 points of presence in Germany, to more quickly and easily aggregate both mobile and fixed broadband traffic between itself and multiple third-party providers of all sizes.

    By utilising the Inter.link system, called FlexPeer, instead of traditional physical internet exchanges, third-party providers can efficiently scale capacity into Vodafone’s fixed and mobile access networks as needed to serve their customers across Europe. They can connect multiple sites over a single ‘Layer 2’ data link, adjusting capacity to actual traffic without affecting the user experience.

    Initial launch in Germany

    Vodafone, in partnership with Inter.link, will launch the service in Germany next month, where Vodafone currently manages over 4,000 interconnections with other providers. The company plans to extend the service to additional countries in 2026.

    This model of interconnection has been developed to address the evolving complexities of a rapidly expanding, multi-tiered commercial internet environment. It enhances resilience and minimises operational overheads, while maintaining efficient Internet traffic flow between end users, their providers, and the services being accessed—such as video streaming, messaging, or browsing social media applications.

    Reduce peering costs

    Transitioning to an automated and flexible interconnection system will reduce time, resources, and peering costs (expenses for connecting different networks) for Vodafone and its wholesale customers. This approach is particularly beneficial for managing the numerous points that connect infrastructure to exchange internet traffic directly. It also puts less strain on the engineering team that plan where the traffic goes when volumes increase.

    Focus on customer service

    By integrating Inter.link’s solution at the edge of Vodafone’s networks, Vodafone can concentrate on delivering improved services to other mobile network operators and broadband providers, thereby enhancing its existing carrier services model. Inter.link’s automation streamlines processes and expedites the customer journey by offering single sign-on access and one-click provisioning.

    Vodafone aims to migrate all traffic in Germany from existing Internet Exchange Points to the new system by the end of 2025. In addition to Europe, the two companies will enable third party providers connecting to Vodafone’s wider global network infrastructure to also leverage Inter.link’s automated platform for improved latency, resiliency and quality.

    Continue Reading

  • Peloton recalls 833,000 more bikes over seat post issue

    Peloton recalls 833,000 more bikes over seat post issue

    Peloton stationary bikes for sale at the company’s showroom in Dedham, Massachusetts, U.S., on Wednesday, Feb. 3, 2021.

    Adam Glanzman | Bloomberg | Getty Images

    Peloton is recalling its original Bike+ after receiving reports that the seat post broke and detached from the equipment during use, leading to two injuries, the Consumer Product Safety Commission said in a news release Thursday. 

    The recall impacts 833,000 units, touching every original Bike+ the company has ever sold. The bikes were sold between January 2020 and April 2025 but Peloton stopped manufacturing them in 2022. 

    The recall comes after Peloton received two reports of injuries “due to a fall” after the post broke off, the CPSC said in its release. It received three reports in total about the issue.  

    The CPSC said consumers should immediately stop using the bikes and contact Peloton for a free repair. The company is offering a free seat post that users can install at home, the agency said. 

    In a statement Thursday, Peloton said, “The integrity of our products and our Members’ well-being are our top priorities.” The company encouraged users to request the new part “as soon as possible.”

    The notice Thursday marks the second time Peloton has had to recall one of its bike models due to issues with the seat post. 

    In May 2023, the company recalled every base Bike model that it ever sold, totaling 2.2 million units, after receiving 35 reports of the seat post breaking and detaching during use. The issue led to 13 injuries, including a fractured wrist, lacerations and bruises.

    At the time, the company said the recall led to higher than expected membership churn, as between 15,000 and 20,000 people paused their monthly subscriptions while waiting for the seat post to be replaced. Replacing the parts cost at least $40 million during its fiscal 2023 fourth quarter, the company said at the time. 

    The recall Thursday, the fifth since Peloton’s founding, comes as CEO Peter Stern looks to get the fitness company back to growth and move past the many issues it has faced since its founding. 

    Changing consumer dynamics have plagued the company since the end of the Covid-19 pandemic, but so have its recalls, including one for its Tread+ treadmill in 2021 after a child was killed. 

    Just over a month ago, Peloton relaunched its product assortment, raised prices and unveiled new features ahead of the crucial holiday shopping season. 

    The current quarter is Peloton’s biggest for hardware sales. 

    The company is expected to report first quarter fiscal 2026 earnings after the bell on Thursday.

    Continue Reading

  • Life insurer Brighthouse agrees to $4.1bn takeover by Aquarian – Financial Times

    Life insurer Brighthouse agrees to $4.1bn takeover by Aquarian – Financial Times

    1. Life insurer Brighthouse agrees to $4.1bn takeover by Aquarian  Financial Times
    2. Aquarian Holdings nears $4bn deal to take US insurer Brighthouse private  Financial Times
    3. $4bn insurance deal could be announced as soon as this weekend  Insurance Business America
    4. Brighthouse Financial (NASDAQ:BHF) Shares Gap Up – Still a Buy?  MarketBeat
    5. Aquarian Capital to Acquire Brighthouse Financial  MarketScreener

    Continue Reading

  • Cummins Reports Strong Third Quarter Operating Results, Records Non-Cash Charges Related to its Electrolyzer Business :: Cummins Inc. (CMI)

    Cummins Reports Strong Third Quarter Operating Results, Records Non-Cash Charges Related to its Electrolyzer Business :: Cummins Inc. (CMI)








    • Third quarter revenues of $8.3 billion; GAAP1 Net Income of $536 million, or 6.4% of sales
    • EBITDA in the third quarter was 14.3% of sales; Diluted EPS of $3.86
    • Third quarter results include $240 million, or $1.73 per diluted share, of Accelera non-cash charges

    COLUMBUS, Ind.–(BUSINESS WIRE)–
    Cummins Inc. (NYSE: CMI) today reported results for the third quarter of 2025.

    “Cummins delivered strong operating results in the third quarter, driven by profitable growth in our Power Systems and Distribution segments, due in part to continued rising demand for backup power for data centers. Effective cost management across the company helped navigate through the anticipated sharp decline in the North American truck market,” said Jennifer Rumsey, Chair and CEO. “During the quarter, we recorded non-cash charges related to our electrolyzer business within the Accelera segment, reflecting policy-driven shifts in hydrogen adoption expectations. Due to the significantly weaker prospects for demand, we are undertaking a strategic review of the electrolyzer business.”

    Third quarter revenues of $8.3 billion decreased 2% from the same quarter in 2024. Sales in North America declined 4%, and international revenues increased 2% due to higher demand in China and Europe.

    Net income attributable to Cummins in the third quarter was $536 million, or $3.86 per diluted share, compared to $809 million, or $5.86 per diluted share, in 2024. The current quarter results include Accelera non-cash charges of $240 million, or $1.73 per diluted share. The tax rate in the third quarter was 32.7% due primarily to non-deductible costs related to Accelera non-cash charges and $36 million or $0.26 per diluted share of tax costs related to the implementation of the One Big Beautiful Bill Act.

    Earnings before interest, taxes, depreciation and amortization (EBITDA) in the third quarter were $1.2 billion, or 14.3% of sales, compared to $1.4 billion, or 16.4% of sales, a year ago. EBITDA for the third quarter of 2025 included the costs noted above.

    2025 Outlook:

    Cummins will not be providing an outlook for revenue or profitability for the remainder of 2025.

    “While uncertainty in a number of our end markets persists, our strong third quarter results are a testament to our diversified portfolio, effective cost discipline and commitment to delivering for our customers,” said Rumsey. “Cummins continues to operate from a position of strength as we navigate this dynamic environment, and we look forward to reinstating our financial guidance in February when we provide our outlook for 2026.”

    Third Quarter 2025 Highlights:

    • Cummins increased its quarterly common stock cash dividend from $1.82 to $2.00 per share. The company has increased the quarterly dividend to shareholders for 16 consecutive years.
    • Cummins and Komatsu signed a memorandum of understanding (MOU) to collaborate on the development of hybrid powertrains for surface haulage heavy mining equipment. Building on a strong legacy of diesel engine supply across a wide variety of mining and construction equipment, Cummins and Komatsu will add hybrids to their product roadmaps of power technology solutions for progressive decarbonization in large mining haul truck applications.
    • Cummins was recognized by Forbes as one of America’s best employers for company culture; rated as a top military-friendly employer by Military Friendly®; and named “Best Place to Work for Disability Inclusion” for the fifth consecutive year by achieving a high score of 100 on the Disability Index®.

    1 Generally Accepted Accounting Principles in the U.S.

    Third quarter 2025 detail (all comparisons to same period in 2024):

    Engine Segment

    • Sales – $2.6 billion, down 11%
    • Segment EBITDA – $261 million, or 10.0% of sales, compared to $427 million, or 14.7% of sales
    • Revenues decreased 12% in North America and 5% in international markets due to lower medium-duty and heavy-duty truck demand in the United States and Mexico.

    Components Segment

    • Sales – $2.3 billion, down 15%
    • Segment EBITDA – $292 million, or 12.5% of sales, compared to $351 million, or 12.9% of sales
    • Revenues in North America decreased by 24% and international sales were flat primarily due to lower medium-duty and heavy-duty truck demand in the United States.

    Distribution Segment

    • Sales – $3.2 billion, up 7%
    • Segment EBITDA – $492 million, or 15.5% of sales, compared to $370 million, or 12.5% of sales
    • Revenues in North America increased 13% due to increased demand for power generation, while international sales declined by 3%.

    Power Systems Segment

    • Sales – $2.0 billion, up 18%
    • Segment EBITDA – $457 million, or 22.9% of sales, compared to $328 million, or 19.4% of sales
    • Revenues in North America increased 20% and international sales increased 17% driven primarily by increased power generation demand, particularly for data center markets in North America, India, and China.

    Accelera Segment

    • Sales – $121 million, up 10%
    • Segment EBITDA loss – $336 million, which includes $240 million of non-cash charges related to goodwill impairment and inventory write-downs.
    • Revenues increased due to higher eMobility demand. The company remains committed to pacing and focusing our zero emissions investments on the most promising paths in order to ensure we are set up for long-term success as part of our Destination Zero strategy. These continued investments contributed to the EBITDA losses.

    About Cummins Inc.

    Cummins Inc., a global power leader, is committed to powering a more prosperous world. Since 1919, we have delivered innovative solutions that move people, goods and economies forward. Our five business segments—Engine, Components, Distribution, Power Systems and Accelera™ by Cummins—offer a broad portfolio, including advanced diesel, alternative fuel, electric and hybrid powertrains; integrated power generation systems; critical components such as aftertreatment, turbochargers, fuel systems, controls, transmissions, axles and brakes; and zero-emissions technologies like battery and electric powertrain systems and electrolyzers. With a global footprint, deep technical expertise and an extensive service network, we deliver dependable, cutting-edge solutions tailored to our customers’ needs, supporting them through the energy transition with our Destination Zero strategy. We create value for customers, investors and employees and strengthen communities through our corporate responsibility global priorities: education, equity and environment. Headquartered in Columbus, Indiana, Cummins employs approximately 70,000 people worldwide and earned $3.9 billion on $34.1 billion in sales in 2024. Learn more at www.cummins.com.

    Forward-looking disclosure statement

    Information provided in this release that is not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our forecasts, guidance, preliminary results, expectations, hopes, beliefs and intentions on strategies regarding the future. These forward-looking statements include, without limitation, statements relating to our plans and expectations for our revenues and EBITDA. Our actual future results could differ materially from those projected in such forward-looking statements because of a number of factors, including, but not limited to: any adverse consequences from changes in tariffs and other trade disruptions; any adverse consequences resulting from entering into agreements with the U.S. Environmental Protection Agency, California Air Resources Board, the Environmental and Natural Resources Division of the U.S. Department of Justice and the California Attorney General’s Office to resolve certain regulatory civil claims regarding our emissions certification and compliance process for certain engines primarily used in pick-up truck applications in the U.S., which became final and effective in April 2024, including required additional mitigation projects; adverse reputational impacts and potential resulting legal actions, increased scrutiny from regulatory agencies, as well as unpredictability in the adoption, implementation and enforcement of emission standards around the world; evolving environmental and climate change legislation and regulatory initiatives; changes in international, national and regional trade laws, regulations and policies; changes in taxation; global legal and ethical compliance costs and risks; future bans or limitations on the use of diesel-powered products; raw material, transportation and labor price fluctuations and supply shortages; aligning our capacity and production with our demand; the actions of, and income from, joint ventures and other investees that we do not directly control; large truck manufacturers’ and original equipment manufacturers’ customers discontinuing outsourcing their engine supply needs or experiencing financial distress, or change in control; product recalls; variability in material and commodity costs; the development of new technologies that reduce demand for our current products and services; lower than expected acceptance of new or existing products or services; product liability claims; our sales mix of products; climate change, global warming, more stringent climate change regulations, accords, mitigation efforts, greenhouse gas regulations or other legislation designed to address climate change; our plan to reposition our portfolio of product offerings through exploration of strategic acquisitions, divestitures or exiting the production of certain product lines or product categories and related uncertainties of such decisions; increasing interest rates; challenging markets for talent and ability to attract, develop and retain key personnel; exposure to potential security breaches or other disruptions to our information technology (IT) environment and data security; the use of artificial intelligence in our business and in our products and challenges with properly managing its use; political, economic and other risks from operations in numerous countries including political, economic and social uncertainty and the evolving globalization of our business; competitor activity; increasing competition, including increased global competition among our customers in emerging markets; failure to meet sustainability expectations or standards, or achieve our sustainability goals; labor relations or work stoppages; foreign currency exchange rate changes; the performance of our pension plan assets and volatility of discount rates; the price and availability of energy; continued availability of financing, financial instruments and financial resources in the amounts, at the times and on the terms required to support our future business; and other risks detailed from time to time in our SEC filings, including particularly in the Risk Factors section of our 2024 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the SEC, which are available at https://www.sec.gov or at https://www.cummins.com in the Investor Relations section of our website.

    Presentation of Non-GAAP Financial Information

    EBITDA is a non-GAAP measure used in this release and is defined and reconciled to what management believes to be the most comparable GAAP measure in a schedule attached to this release, except for forward-looking measures of EBITDA where a reconciliation to the corresponding GAAP measures is not available due to the variability, complexity and limited visibility of the non-cash items that are excluded from the non-GAAP outlook measure. Cummins presents this information as it believes it is useful to understanding the Company’s operating performance, and because EBITDA is a measure used internally to assess the performance of the operating units.

    Webcast information

    Cummins management will host a teleconference to discuss these results today at 10 a.m. ET. This teleconference will be webcast and available on the Investor Relations section of the Cummins website at www.cummins.com. Participants wishing to view the visuals available with the audio are encouraged to sign-in a few minutes prior to the start of the teleconference.

    CUMMINS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF NET INCOME

    (Unaudited) (a)

     

     

     

    Three months ended

     

     

    September 30,

    In millions, except per share amounts

     

     

    2025

     

     

    2024

    NET SALES

     

    $

    8,317

     

    $

    8,456

    Cost of sales

     

     

    6,188

     

     

    6,285

    GROSS MARGIN

     

     

    2,129

     

     

    2,171

    OPERATING EXPENSES AND INCOME

     

     

     

     

    Selling, general and administrative expenses

     

     

    789

     

     

    807

    Research, development and engineering expenses

     

     

    345

     

     

    359

    Equity, royalty and interest income from investees

     

     

    104

     

     

    99

    Other operating expense, net

     

     

    247

     

     

    54

    OPERATING INCOME

     

     

    852

     

     

    1,050

    Interest expense

     

     

    83

     

     

    83

    Other income, net

     

     

    61

     

     

    76

    INCOME BEFORE INCOME TAXES

     

     

    830

     

     

    1,043

    Income tax expense

     

     

    271

     

     

    200

    CONSOLIDATED NET INCOME

     

     

    559

     

     

    843

    Less: Net income attributable to noncontrolling interests

     

     

    23

     

     

    34

    NET INCOME ATTRIBUTABLE TO CUMMINS INC.

     

    $

    536

     

    $

    809

     

     

     

     

     

    EARNINGS PER COMMON SHARE ATTRIBUTABLE TO CUMMINS INC.

     

     

     

     

    Basic

     

    $

    3.88

     

    $

    5.90

    Diluted

     

    $

    3.86

     

    $

    5.86

     

     

     

     

     

    WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING

     

     

     

     

    Basic

     

     

    138.0

     

     

    137.2

    Diluted

     

     

    138.8

     

     

    138.1

     

     

     

     

     

    (a) Prepared on an unaudited basis in accordance with accounting principles generally accepted in the United States of America.

     

     

    Nine months ended

     

     

    September 30,

    In millions, except per share amounts

     

     

    2025

     

     

    2024

    NET SALES

     

    $

    25,134

     

    $

    25,655

    Cost of sales

     

     

    18,569

     

     

    19,250

    GROSS MARGIN

     

     

    6,565

     

     

    6,405

    OPERATING EXPENSES AND INCOME

     

     

     

     

    Selling, general and administrative expenses

     

     

    2,339

     

     

    2,474

    Research, development and engineering expenses

     

     

    1,046

     

     

    1,107

    Equity, royalty and interest income from investees

     

     

    353

     

     

    325

    Other operating expense, net

     

     

    321

     

     

    131

    OPERATING INCOME

     

     

    3,212

     

     

    3,018

    Interest expense

     

     

    247

     

     

    281

    Other income, net

     

     

    207

     

     

    1,504

    INCOME BEFORE INCOME TAXES

     

     

    3,172

     

     

    4,241

    Income tax expense

     

     

    835

     

     

    618

    CONSOLIDATED NET INCOME

     

     

    2,337

     

     

    3,623

    Less: Net income attributable to noncontrolling interests

     

     

    87

     

     

    95

    NET INCOME ATTRIBUTABLE TO CUMMINS INC.

     

    $

    2,250

     

    $

    3,528

     

     

     

     

     

    EARNINGS PER COMMON SHARE ATTRIBUTABLE TO CUMMINS INC.

     

     

     

     

    Basic

     

    $

    16.33

     

    $

    25.47

    Diluted

     

    $

    16.23

     

    $

    25.31

     

     

     

     

     

    WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING

     

     

     

     

    Basic

     

     

    137.8

     

     

    138.5

    Diluted

     

     

    138.6

     

     

    139.4

     

     

     

     

     

    (a) Prepared on an unaudited basis in accordance with accounting principles generally accepted in the United States of America.

    CUMMINS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited) (a)

     

    In millions, except par value

     

    September 30,

    2025

     

    December 31,

    2024

    ASSETS

     

     

     

     

    Current assets

     

     

     

     

    Cash and cash equivalents

     

    $

    2,566

     

     

    $

    1,671

     

    Marketable securities

     

     

    593

     

     

     

    593

     

    Total cash, cash equivalents and marketable securities

     

     

    3,159

     

     

     

    2,264

     

    Accounts and notes receivable, net

     

     

    5,640

     

     

     

    5,181

     

    Inventories

     

     

    6,256

     

     

     

    5,742

     

    Prepaid expenses and other current assets

     

     

    1,665

     

     

     

    1,565

     

    Total current assets

     

     

    16,720

     

     

     

    14,752

     

    Long-term assets

     

     

     

     

    Property, plant and equipment, net

     

     

    6,658

     

     

     

    6,356

     

    Investments and advances related to equity method investees

     

     

    1,972

     

     

     

    1,889

     

    Goodwill

     

     

    2,222

     

     

     

    2,370

     

    Other intangible assets, net

     

     

    2,345

     

     

     

    2,351

     

    Pension assets

     

     

    1,157

     

     

     

    1,189

     

    Other assets

     

     

    2,564

     

     

     

    2,633

     

    Total assets

     

    $

    33,638

     

     

    $

    31,540

     

     

     

     

     

     

    LIABILITIES

     

     

     

     

    Current liabilities

     

     

     

     

    Accounts payable (principally trade)

     

    $

    3,819

     

     

    $

    3,951

     

    Loans payable

     

     

    315

     

     

     

    356

     

    Commercial paper

     

     

    353

     

     

     

    1,259

     

    Current maturities of long-term debt

     

     

    122

     

     

     

    660

     

    Accrued compensation, benefits and retirement costs

     

     

    770

     

     

     

    1,084

     

    Current portion of accrued product warranty

     

     

    660

     

     

     

    679

     

    Current portion of deferred revenue

     

     

    1,600

     

     

     

    1,347

     

    Other accrued expenses

     

     

    1,815

     

     

     

    1,898

     

    Total current liabilities

     

     

    9,454

     

     

     

    11,234

     

    Long-term liabilities

     

     

     

     

    Long-term debt

     

     

    6,824

     

     

     

    4,784

     

    Deferred revenue

     

     

    1,119

     

     

     

    1,065

     

    Other liabilities

     

     

    3,143

     

     

     

    3,149

     

    Total liabilities

     

    $

    20,540

     

     

    $

    20,232

     

     

     

     

     

     

    EQUITY

     

     

     

     

    Cummins Inc. shareholders’ equity

     

     

     

     

    Common stock, $2.50 par value, 500 shares authorized, 222.5 and 222.5 shares issued

     

    $

    2,651

     

     

    $

    2,636

     

    Retained earnings

     

     

    22,300

     

     

     

    20,828

     

    Treasury stock, at cost, 84.5 and 85.1 shares

     

     

    (10,676

    )

     

     

    (10,748

    )

    Accumulated other comprehensive loss

     

     

    (2,211

    )

     

     

    (2,445

    )

    Total Cummins Inc. shareholders’ equity

     

     

    12,064

     

     

     

    10,271

     

    Noncontrolling interests

     

     

    1,034

     

     

     

    1,037

     

    Total equity

     

    $

    13,098

     

     

    $

    11,308

     

    Total liabilities and equity

     

    $

    33,638

     

     

    $

    31,540

     

     

     

     

     

     

    (a) Prepared on an unaudited basis in accordance with accounting principles generally accepted in the United States of America.

    CUMMINS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited) (a)

     

     

     

    Three months ended

     

     

    September 30,

    In millions

     

     

    2025

     

     

     

    2024

     

    CASH FLOWS FROM OPERATING ACTIVITIES

     

     

     

     

    Consolidated net income

     

    $

    559

     

     

    $

    843

     

    Adjustments to reconcile consolidated net income to net cash provided by operating activities

     

     

    Depreciation and amortization

     

     

    277

     

     

     

    266

     

    Deferred income taxes

     

     

    206

     

     

     

    (7

    )

    Equity in income of investees, net of dividends

     

     

    50

     

     

     

    12

     

    Pension and OPEB expense

     

     

    21

     

     

     

    9

     

    Pension contributions and OPEB payments

     

     

    (12

    )

     

     

    (13

    )

    Changes in current assets and liabilities, net of acquisitions

     

     

     

     

    Accounts and notes receivable

     

     

    177

     

     

     

    270

     

    Inventories

     

     

    (10

    )

     

     

    (257

    )

    Other current assets

     

     

    26

     

     

     

    (219

    )

    Accounts payable

     

     

    (295

    )

     

     

    (236

    )

    Accrued expenses

     

     

    43

     

     

     

    (67

    )

    Other, net

     

     

    263

     

     

     

    39

     

    Net cash provided by operating activities

     

     

    1,305

     

     

     

    640

     

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES

     

     

     

     

    Capital expenditures

     

     

    (298

    )

     

     

    (259

    )

    Investments in and net advances to equity investees

     

     

    (9

    )

     

     

    (78

    )

    Investments in marketable securities—acquisitions

     

     

    (350

    )

     

     

    (349

    )

    Investments in marketable securities—liquidations

     

     

    495

     

     

     

    428

     

    Other, net

     

     

    (69

    )

     

     

    (5

    )

    Net cash used in investing activities

     

     

    (231

    )

     

     

    (263

    )

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES

     

     

     

     

    Proceeds from borrowings

     

     

    86

     

     

     

    141

     

    Net borrowings of commercial paper

     

     

     

     

     

    55

     

    Payments on borrowings and finance lease obligations

     

     

    (617

    )

     

     

    (163

    )

    Dividend payments on common stock

     

     

    (276

    )

     

     

    (250

    )

    Other, net

     

     

    (20

    )

     

     

    (26

    )

    Net cash used in financing activities

     

     

    (827

    )

     

     

    (243

    )

    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

     

     

     

     

     

    9

     

    Net increase in cash and cash equivalents

     

     

    247

     

     

     

    143

     

    Cash and cash equivalents at beginning of period

     

     

    2,319

     

     

     

    1,590

     

    CASH AND CASH EQUIVALENTS AT END OF PERIOD

     

    $

    2,566

     

     

    $

    1,733

     

     

     

     

     

     

    (a) Prepared on an unaudited basis in accordance with accounting principles generally accepted in the United States of America.

     

     

    Nine months ended

     

     

    September 30,

    In millions

     

     

    2025

     

     

     

    2024

     

    CASH FLOWS FROM OPERATING ACTIVITIES

     

     

     

     

    Consolidated net income

     

    $

    2,337

     

     

    $

    3,623

     

    Adjustments to reconcile consolidated net income to net cash provided by operating activities

     

     

     

     

    Gain related to divestiture of Atmus

     

     

     

     

     

    (1,333

    )

    Depreciation and amortization

     

     

    825

     

     

     

    794

     

    Deferred income taxes

     

     

    68

     

     

     

    (106

    )

    Equity in income of investees, net of dividends

     

     

    (38

    )

     

     

    (74

    )

    Pension and OPEB expense

     

     

    60

     

     

     

    28

     

    Pension contributions and OPEB payments

     

     

    (38

    )

     

     

    (72

    )

    Changes in current assets and liabilities, net of acquisitions and divestiture

     

     

     

     

    Accounts and notes receivable

     

     

    (466

    )

     

     

    109

     

    Inventories

     

     

    (446

    )

     

     

    (726

    )

    Other current assets

     

     

    (146

    )

     

     

    (370

    )

    Accounts payable

     

     

    (147

    )

     

     

    27

     

    Accrued expenses

     

     

    (201

    )

     

     

    (2,000

    )

    Other, net

     

     

    279

     

     

     

    165

     

    Net cash provided by operating activities

     

     

    2,087

     

     

     

    65

     

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES

     

     

     

     

    Capital expenditures

     

     

    (691

    )

     

     

    (668

    )

    Investments in and net advances to equity investees

     

     

    (63

    )

     

     

    (133

    )

    Acquisition of businesses, net of cash acquired

     

     

    (12

    )

     

     

    (58

    )

    Investments in marketable securities—acquisitions

     

     

    (1,133

    )

     

     

    (1,062

    )

    Investments in marketable securities—liquidations

     

     

    1,131

     

     

     

    1,113

     

    Cash associated with Atmus divestiture

     

     

     

     

     

    (174

    )

    Other, net

     

     

    (78

    )

     

     

    (87

    )

    Net cash used in investing activities

     

     

    (846

    )

     

     

    (1,069

    )

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES

     

     

     

     

    Proceeds from borrowings

     

     

    2,232

     

     

     

    2,623

     

    Net (payments) borrowings of commercial paper

     

     

    (906

    )

     

     

    140

     

    Payments on borrowings and finance lease obligations

     

     

    (827

    )

     

     

    (1,386

    )

    Dividend payments on common stock

     

     

    (778

    )

     

     

    (719

    )

    Payments for purchase of redeemable noncontrolling interests

     

     

    (55

    )

     

     

     

    Other, net

     

     

    (69

    )

     

     

    (94

    )

    Net cash (used in) provided by financing activities

     

     

    (403

    )

     

     

    564

     

    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

     

     

    57

     

     

     

    (6

    )

    Net increase (decrease) in cash and cash equivalents

     

     

    895

     

     

     

    (446

    )

    Cash and cash equivalents at beginning of year

     

     

    1,671

     

     

     

    2,179

     

    CASH AND CASH EQUIVALENTS AT END OF PERIOD

     

    $

    2,566

     

     

    $

    1,733

     

     

     

     

     

     

    (a) Prepared on an unaudited basis in accordance with accounting principles generally accepted in the United States of America.

    CUMMINS INC. AND SUBSIDIARIES

    SEGMENT INFORMATION

    (Unaudited)

     

    In millions

     

    Engine

     

    Components

     

    Distribution

     

    Power Systems

     

    Accelera

     

    Total Segments

     

    Intersegment Eliminations (1)

     

    Total

    Three months ended September 30, 2025

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    External sales

     

    $

    1,922

     

     

    $

    1,986

     

     

    $

    3,170

     

     

    $

    1,126

     

     

    $

    113

     

     

    $

    8,317

     

     

    $

     

     

    $

    8,317

     

    Intersegment sales

     

     

    683

     

     

     

    343

     

     

     

    2

     

     

     

    870

     

     

     

    8

     

     

     

    1,906

     

     

     

    (1,906

    )

     

     

     

    Total sales

     

     

    2,605

     

     

     

    2,329

     

     

     

    3,172

     

     

     

    1,996

     

     

     

    121

     

     

     

    10,223

     

     

     

    (1,906

    )

     

     

    8,317

     

    Research, development and engineering expenses

     

     

    159

     

     

     

    70

     

     

     

    14

     

     

     

    62

     

     

     

    40

     

     

     

    345

     

     

     

     

     

     

    345

     

    Equity, royalty and interest income (loss) from investees

     

     

    54

     

     

     

    7

     

     

     

    23

     

     

     

    26

     

     

     

    (6

    )

     

     

    104

     

     

     

     

     

     

    104

     

    Interest income

     

     

    11

     

     

     

    8

     

     

     

    6

     

     

     

    4

     

     

     

     

     

     

    29

     

     

     

     

     

     

    29

     

    EBITDA (2)

     

     

    261

     

     

     

    292

     

     

     

    492

     

     

     

    457

     

     

     

    (336

    )

    (3)

     

    1,166

     

     

     

    21

     

     

     

    1,187

     

    Depreciation and amortization (4)

     

     

    71

     

     

     

    122

     

     

     

    32

     

     

     

    36

     

     

     

    13

     

     

     

    274

     

     

     

     

     

     

    274

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    EBITDA as a percentage of segment sales

     

     

    10.0

    %

     

     

    12.5

    %

     

     

    15.5

    %

     

     

    22.9

    %

     

     

    NM

     

     

     

    11.4

    %

     

     

     

     

    14.3

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended September 30, 2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    External sales

     

    $

    2,215

     

     

    $

    2,287

     

     

    $

    2,942

     

     

    $

    912

     

     

    $

    100

     

     

    $

    8,456

     

     

    $

     

     

    $

    8,456

     

    Intersegment sales

     

     

    698

     

     

     

    437

     

     

     

    10

     

     

     

    775

     

     

     

    10

     

     

     

    1,930

     

     

     

    (1,930

    )

     

     

     

    Total sales

     

     

    2,913

     

     

     

    2,724

     

     

     

    2,952

     

     

     

    1,687

     

     

     

    110

     

     

     

    10,386

     

     

     

    (1,930

    )

     

     

    8,456

     

    Research, development and engineering expenses

     

     

    147

     

     

     

    85

     

     

     

    13

     

     

     

    57

     

     

     

    57

     

     

     

    359

     

     

     

     

     

     

    359

     

    Equity, royalty and interest income (loss) from investees

     

     

    53

     

     

     

    12

     

     

     

    25

     

     

     

    20

     

     

     

    (11

    )

     

     

    99

     

     

     

     

     

     

    99

     

    Interest income

     

     

    2

     

     

     

    4

     

     

     

    7

     

     

     

    1

     

     

     

     

     

     

    14

     

     

     

     

     

     

    14

     

    EBITDA (2)

     

     

    427

     

     

     

    351

     

     

     

    370

     

     

     

    328

     

     

     

    (115

    )

     

     

    1,361

     

     

     

    28

     

     

     

    1,389

     

    Depreciation and amortization (4)

     

     

    62

     

     

     

    121

     

     

     

    31

     

     

     

    33

     

     

     

    16

     

     

     

    263

     

     

     

     

     

     

    263

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    EBITDA as a percentage of segment sales

     

     

    14.7

    %

     

     

    12.9

    %

     

     

    12.5

    %

     

     

    19.4

    %

     

     

    NM

     

     

     

    13.1

    %

     

     

     

     

    16.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    “NM” – not meaningful information

    (1)

    Included intersegment sales, intersegment profit in inventory and unallocated corporate expenses. There were no significant unallocated corporate expenses for the three months ended September 30, 2025 and 2024.

    (2)

    EBITDA is defined as earnings or losses before interest expense, income taxes, depreciation and amortization and noncontrolling interests. We believe EBITDA is a useful measure of our operating performance as it assists investors and debt holders in comparing our performance on a consistent basis without regard to financing methods, capital structure, income taxes or depreciation and amortization methods, which can vary significantly depending upon many factors.

    (3)

    Included a $210 million goodwill impairment charge and a $30 million inventory write-down for three months ended September 30, 2025.

    (4)

    Depreciation and amortization, as shown on a segment basis, excludes the amortization of debt discount and deferred costs included in our Condensed Consolidated Statements of Net Income as interest expense. A portion of depreciation expense is included in research, development and engineering expenses.

    In millions

     

    Engine

     

    Components

     

    Distribution

     

    Power Systems

     

    Accelera

     

    Total Segments

     

    Intersegment Eliminations (1)

     

    Total

    Nine months ended September 30, 2025

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    External sales

     

    $

    6,124

     

     

    $

    6,551

     

     

    $

    9,106

     

     

    $

    3,052

     

     

    $

    301

     

     

    $

    25,134

     

     

    $

     

     

    $

    25,134

     

    Intersegment sales

     

     

    2,151

     

     

     

    1,153

     

     

     

    14

     

     

     

    2,482

     

     

     

    28

     

     

     

    5,828

     

     

     

    (5,828

    )

     

     

     

    Total sales

     

     

    8,275

     

     

     

    7,704

     

     

     

    9,120

     

     

     

    5,534

     

     

     

    329

     

     

     

    30,962

     

     

     

    (5,828

    )

     

     

    25,134

     

    Research, development and engineering expenses

     

     

    465

     

     

     

    222

     

     

     

    42

     

     

     

    188

     

     

     

    129

     

     

     

    1,046

     

     

     

     

     

     

    1,046

     

    Equity, royalty and interest income (loss) from investees

     

     

    187

     

     

     

    24

     

     

     

    77

     

     

     

    82

     

     

     

    (17

    )

     

     

    353

     

     

     

     

     

     

    353

     

    Interest income

     

     

    29

     

     

     

    25

     

     

     

    18

     

     

     

    12

     

     

     

    1

     

     

     

    85

     

     

     

     

     

     

    85

     

    EBITDA (2)

     

     

    1,119

     

     

     

    1,071

     

     

     

    1,313

     

     

     

    1,276

     

     

     

    (522

    )

    (3)

     

    4,257

     

     

     

    (23

    )

     

     

    4,234

     

    Depreciation and amortization (4)

     

     

    206

     

     

     

    371

     

     

     

    96

     

     

     

    104

     

     

     

    38

     

     

     

    815

     

     

     

     

     

     

    815

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    EBITDA as a percentage of total sales

     

     

    13.5

    %

     

     

    13.9

    %

     

     

    14.4

    %

     

     

    23.1

    %

     

     

    NM

     

     

     

    13.7

    %

     

     

     

     

    16.8

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Nine months ended September 30, 2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    External sales

     

    $

    6,923

     

     

    $

    7,647

     

     

    $

    8,292

     

     

    $

    2,508

     

     

    $

    285

     

     

    $

    25,655

     

     

    $

     

     

    $

    25,655

     

    Intersegment sales

     

     

    2,069

     

     

     

    1,391

     

     

     

    24

     

     

     

    2,157

     

     

     

    29

     

     

     

    5,670

     

     

     

    (5,670

    )

     

     

     

    Total sales

     

     

    8,992

     

     

     

    9,038

     

     

     

    8,316

     

     

     

    4,665

     

     

     

    314

     

     

     

    31,325

     

     

     

    (5,670

    )

     

     

    25,655

     

    Research, development and engineering expenses

     

     

    468

     

     

     

    250

     

     

     

    41

     

     

     

    180

     

     

     

    166

     

     

     

    1,105

     

     

     

    2

     

     

     

    1,107

     

    Equity, royalty and interest income (loss) from investees

     

     

    158

     

     

     

    51

     

     

     

    73

     

     

     

    65

     

     

     

    (22

    )

     

     

    325

     

     

     

     

     

     

    325

     

    Interest income

     

     

    16

     

     

     

    21

     

     

     

    29

     

     

     

    7

     

     

     

     

     

     

    73

     

     

     

     

     

     

    73

     

    EBITDA (2)

     

     

    1,286

     

     

     

    1,230

     

    (5)

     

    978

     

     

     

    866

     

     

     

    (333

    )

     

     

    4,027

     

     

     

    1,279

     

     

     

    5,306

     

    Depreciation and amortization (4)

     

     

    181

     

     

     

    367

     

     

     

    92

     

     

     

    99

     

     

     

    45

     

     

     

    784

     

     

     

     

     

     

    784

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    EBITDA as a percentage of total sales

     

     

    14.3

    %

     

     

    13.6

    %

     

     

    11.8

    %

     

     

    18.6

    %

     

     

    NM

     

     

     

    12.9

    %

     

     

     

     

    20.7

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    “NM” – not meaningful information

    (1)

    Included intersegment sales, intersegment profit in inventory and unallocated corporate expenses. There were no significant unallocated corporate expenses for the nine months ended September 30, 2025. The nine months ended September 30, 2024, included a $1.3 billion gain related to the divestiture of Atmus Filtration Technologies Inc. (Atmus) and $14 million of costs associated with the divestiture of Atmus.

    (2)

    EBITDA is defined as earnings or losses before interest expense, income taxes, depreciation and amortization and noncontrolling interests. We believe EBITDA is a useful measure of our operating performance as it assists investors and debt holders in comparing our performance on a consistent basis without regard to financing methods, capital structure, income taxes or depreciation and amortization methods, which can vary significantly depending upon many factors.

    (3)

    Included a $210 million goodwill impairment charge and a $30 million inventory write-down for nine months ended September 30, 2025.

    (4)

    Depreciation and amortization, as shown on a segment basis, excluded the amortization of debt discount and deferred costs included in the Condensed Consolidated Statements of Net Income as interest expense. The amortization of debt discount and deferred costs was $10 million and $10 million for the nine months ended September 30, 2025 and 2024, respectively. A portion of depreciation expense is included in research, development and engineering expenses.

    (5)

    Included $21 million of costs associated with the divestiture of Atmus for the nine months ended September 30, 2024.

    CUMMINS INC. AND SUBSIDIARIES

    SELECT FOOTNOTE DATA

    (Unaudited)

     

    EQUITY, ROYALTY AND INTEREST INCOME FROM INVESTEES

     

    Equity, royalty and interest income from investees included in our Condensed Consolidated Statements of Net Income for the reporting periods was as follows:

     

     

     

    Three months ended

     

    Nine months ended

     

     

    September 30,

     

    September 30,

    In millions

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

    Manufacturing entities

     

     

     

     

     

     

     

     

    Chongqing Cummins Engine Company, Ltd.

     

    $

    23

     

    $

    15

     

    $

    68

     

    $

    51

    Beijing Foton Cummins Engine Co., Ltd.

     

     

    17

     

     

    6

     

     

    47

     

     

    29

    Dongfeng Cummins Engine Company, Ltd.

     

     

    13

     

     

    14

     

     

    52

     

     

    51

    Tata Cummins, Ltd.

     

     

    6

     

     

    6

     

     

    23

     

     

    22

    All other manufacturers

     

     

    6

     

     

    7

     

     

    27

     

     

    41

    Distribution entities

     

     

     

     

     

     

     

     

    Komatsu Cummins Chile, Ltda.

     

     

    12

     

     

    15

     

     

    41

     

     

    42

    All other distributors

     

     

    5

     

     

    3

     

     

    17

     

     

    10

    Cummins share of net income

     

     

    82

     

     

    66

     

     

    275

     

     

    246

    Royalty and interest income

     

     

    22

     

     

    33

     

     

    78

     

     

    79

    Equity, royalty and interest income from investees

     

    $

    104

     

    $

    99

     

    $

    353

     

    $

    325

     

     

     

     

     

     

     

     

     

    GOODWILL IMPAIRMENT AND INVENTORY WRITE-DOWN

     

    During the third quarter of 2025, in our Accelera segment, we observed rapidly deteriorating conditions in our electrolyzer markets and overall hydrogen markets, along with significant uncertainty in the alternative power markets resulting from reductions in government incentives. As a result, we determined that a triggering event occurred for our electrolyzer reporting unit, warranting an interim impairment test of goodwill and the related asset group. We also re-evaluated the recoverability of certain inventory in this business due to the declining customer demand, resulting in a $30 million, or $0.22 per diluted share, excess and obsolete inventory write-down recorded in cost of sales. We concluded that the undiscounted cash flows exceeded the carrying value of the related asset group and thus an impairment did not exist for the related long-lived assets. However, we determined that on a fair value basis our goodwill was fully impaired and recorded a charge of $210 million, or $1.51 per diluted share, in other operating expense, net. The fair value of this reporting unit was determined using primarily a discounted cash flow model (a form of the income approach). This model incorporated a number of assumptions and judgements surrounding current market and economic conditions, internal forecasts of future business performance including short and long-term growth rates, earnings or losses before interest expense, income taxes, depreciation and amortization and noncontrolling interests (EBITDA) margins and discount rates. The $240 million of charges were non-deductible for income taxes purposes. These non-cash charges were reflected in net cash provided by operating activities as a change in inventory of $30 million and other, net of $210 million.

     

    INCOME TAXES

     

    On July 4, 2025, the One Big Beautiful Bill Act (The Act) was signed into law, enacting significant changes to U.S. federal income tax rules affecting corporations, such as the ability to immediately deduct domestic research and development costs, restoration of elective 100 percent bonus depreciation for qualified property and changes to the international tax provisions. Implementation of The Act resulted in an increase to tax expense of $36 million, or $0.26 per diluted share, in the third quarter of 2025, primarily due to a reduction in the foreign income deduction and changes to the research and development tax credit.

     

    Our effective tax rate for 2025 is expected to approximate 26.5 percent, excluding any discrete items that may arise, which is a 2 percent increase over our prior estimates. This increase is attributable to the impacts of The Act and the non-deductible goodwill impairment and inventory write-down.

     

    Our effective tax rates for the three and nine months ended September 30, 2025, were 32.7 percent and 26.3 percent, respectively. Our effective tax rates for the three and nine months ended September 30, 2024, were 19.2 percent and 14.6 percent, respectively.

     

    The three months ended September 30, 2025, contained net unfavorable discrete tax items of $4 million, $0.03 per diluted share, primarily due to $32 million of unfavorable return to provision adjustments and net $1 million of other unfavorable tax items, partially offset by $25 million of favorable adjustments for uncertain tax positions and $4 million of favorable adjustments for share-based compensation.

     

    The nine months ended September 30, 2025, contained net favorable discrete tax items of $6 million, $0.04 per diluted share, primarily due to $30 million of favorable adjustments for uncertain tax positions and $12 million of favorable adjustments for share-based compensation, partially offset by $32 million of unfavorable return to provision adjustments and net $4 million of other unfavorable tax items.

     

    The three months ended September 30, 2024, contained net favorable discrete tax items of $36 million, or $0.26 per share, primarily due to $20 million of favorable adjustments from tax return amendments, $15 million of favorable return to provision adjustments and $2 million of favorable share-based compensation tax benefits, partially offset by $1 million of other unfavorable tax items.

     

    The nine months ended September 30, 2024, contained favorable discrete tax items primarily due to the $1.3 billion non-taxable gain on the Atmus split-off. Other discrete tax items were net favorable by $66 million, or $0.47 per share, primarily due to $21 million of favorable adjustments related to audit settlements, $20 million of favorable adjustments from tax return amendments, $18 million of favorable return to provision adjustments and $17 million of favorable share-based compensation tax benefits, partially offset by $7 million of unfavorable adjustments for uncertain tax positions and $3 million of other unfavorable adjustments.

     

    Reconciliation of Non GAAP measures – Earnings before interest, income taxes, depreciation and amortization and noncontrolling interests (EBITDA)

     

    We believe EBITDA is a useful measure of our operating performance as it assists investors and debt holders in comparing our performance on a consistent basis without regard to financing methods, capital structure, income taxes or depreciation and amortization methods, which can vary significantly depending upon many factors. We believe EBITDA excluding special items, as noted in the table below, is a useful measure of our operating performance. This statement excludes forward looking measures of EBITDA where a reconciliation to the corresponding accounting principles generally accepted in the United States (GAAP) measures is not available due to the variability, complexity and limited visibility of non-cash items that are excluded from the non-GAAP outlook measure.

     

    EBITDA is not in accordance with, or an alternative for, GAAP and may not be consistent with measures used by other companies. It should be considered supplemental data; however, the amounts included in the EBITDA calculation are derived from amounts included in our Condensed Consolidated Statements of Net Income. Below is a reconciliation of net income attributable to Cummins Inc. to EBITDA for each of the applicable periods:

     

     

    Three months ended

     

    Nine months ended

     

     

    September 30,

     

    September 30,

    In millions

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Net income attributable to Cummins Inc.

     

    $

    536

     

     

    $

    809

     

     

    $

    2,250

     

     

    $

    3,528

     

     

     

     

     

     

     

     

     

     

    Net income attributable to Cummins Inc., as a percentage of net sales

     

     

    6.4

    %

     

     

    9.6

    %

     

     

    9.0

    %

     

     

    13.8

    %

     

     

     

     

     

     

     

     

     

    Add:

     

     

     

     

     

     

     

     

    Net income attributable to noncontrolling interests

     

     

    23

     

     

     

    34

     

     

     

    87

     

     

     

    95

     

    Consolidated net income

     

     

    559

     

     

     

    843

     

     

     

    2,337

     

     

     

    3,623

     

     

     

     

     

     

     

     

     

     

    Add:

     

     

     

     

     

     

     

     

    Interest expense

     

     

    83

     

     

     

    83

     

     

     

    247

     

     

     

    281

     

    Income tax expense

     

     

    271

     

     

     

    200

     

     

     

    835

     

     

     

    618

     

    Depreciation and amortization

     

     

    274

     

     

     

    263

     

     

     

    815

     

     

     

    784

     

    EBITDA

     

    $

    1,187

     

     

    $

    1,389

     

     

    $

    4,234

     

     

    $

    5,306

     

     

     

     

     

     

     

     

     

     

    EBITDA, as a percentage of net sales

     

     

    14.3

    %

     

     

    16.4

    %

     

     

    16.8

    %

     

     

    20.7

    %

     

     

     

     

     

     

     

     

     

    Special items:

     

     

     

     

     

     

     

     

    Accelera goodwill impairment

     

     

    210

     

     

     

     

     

     

    210

     

     

     

     

    Accelera inventory write-down

     

     

    30

     

     

     

     

     

     

    30

     

     

     

     

    Atmus divestiture costs

     

     

     

     

     

     

     

     

     

     

     

    35

     

    Restructuring actions

     

     

     

     

     

     

     

     

     

     

     

    29

     

    Gain related to the divestiture of Atmus

     

     

     

     

     

     

     

     

     

     

     

    (1,333

    )

    EBITDA, excluding special items

     

    $

    1,427

     

     

    $

    1,389

     

     

    $

    4,474

     

     

    $

    4,037

     

     

     

     

     

     

     

     

     

     

    EBITDA, excluding special items, as a percentage of net sales

     

     

    17.2

    %

     

     

    16.4

    %

     

     

    17.8

    %

     

     

    15.7

    %

    CUMMINS INC. AND SUBSIDIARIES

    SEGMENT SALES DATA

    (Unaudited)

     

    Engine Segment Sales by Market and Unit Shipments by Engine Classification

     

    Sales for our Engine segment by market were as follows:

     

    2025

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Heavy-duty truck

     

    $

    921

     

    $

    976

     

    $

    772

     

    $

     

    $

    2,669

    Medium-duty truck and bus

     

     

    986

     

     

    950

     

     

    784

     

     

     

     

    2,720

    Light-duty automotive

     

     

    421

     

     

    486

     

     

    583

     

     

     

     

    1,490

    Off-highway

     

     

    443

     

     

    487

     

     

    466

     

     

     

     

    1,396

    Total sales

     

    $

    2,771

     

    $

    2,899

     

    $

    2,605

     

    $

     

    $

    8,275

     

     

     

     

     

     

     

     

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Heavy-duty truck

     

    $

    1,059

     

    $

    1,184

     

    $

    1,021

     

    $

    980

     

    $

    4,244

    Medium-duty truck and bus

     

     

    995

     

     

    1,074

     

     

    1,073

     

     

    1,024

     

     

    4,166

    Light-duty automotive

     

     

    438

     

     

    461

     

     

    395

     

     

    301

     

     

    1,595

    Off-highway

     

     

    436

     

     

    432

     

     

    424

     

     

    415

     

     

    1,707

    Total sales

     

    $

    2,928

     

    $

    3,151

     

    $

    2,913

     

    $

    2,720

     

    $

    11,712

    Unit shipments by engine classification (including unit shipments to Power Systems and off-highway engine units included in their respective classification) were as follows:

     

    2025

     

     

     

     

     

     

     

     

     

     

    Units (1)

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Heavy-duty

     

    26,700

     

    29,600

     

    22,400

     

     

    78,700

    Medium-duty

     

    75,200

     

    73,400

     

    63,100

     

     

    211,700

    Light-duty

     

    39,100

     

    44,000

     

    49,600

     

     

    132,700

    Total units

     

    141,000

     

    147,000

     

    135,100

     

     

    423,100

     

     

     

     

     

     

     

     

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

    Units (1)

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Heavy-duty

     

    33,600

     

    37,500

     

    32,400

     

    29,400

     

    132,900

    Medium-duty

     

    75,800

     

    79,600

     

    79,200

     

    75,700

     

    310,300

    Light-duty

     

    54,800

     

    57,200

     

    41,400

     

    36,000

     

    189,400

    Total units

     

    164,200

     

    174,300

     

    153,000

     

    141,100

     

    632,600

     

     

     

     

     

     

     

     

     

     

     

    (1) Unit shipments exclude aftermarket parts.

    Components Segment Sales by Business

     

    Sales for our Components segment by business were as follows:

     

    2025

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Drivetrain and braking systems

     

    $

    1,056

     

    $

    1,095

     

    $

    917

     

    $

     

    $

    3,068

    Emission solutions

     

     

    902

     

     

    900

     

     

    788

     

     

     

     

    2,590

    Components and software

     

     

    595

     

     

    587

     

     

    537

     

     

     

     

    1,719

    Automated transmissions

     

     

    117

     

     

    123

     

     

    87

     

     

     

     

    327

    Total sales

     

    $

    2,670

     

    $

    2,705

     

    $

    2,329

     

    $

     

    $

    7,704

     

     

     

     

     

     

     

     

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Drivetrain and braking systems

     

    $

    1,232

     

    $

    1,256

     

    $

    1,131

     

    $

    1,114

     

    $

    4,733

    Emission solutions

     

     

    971

     

     

    941

     

     

    864

     

     

    825

     

     

    3,601

    Components and software

     

     

    611

     

     

    623

     

     

    581

     

     

    589

     

     

    2,404

    Automated transmissions

     

     

    165

     

     

    162

     

     

    148

     

     

    113

     

     

    588

    Atmus (1)

     

     

    353

     

     

     

     

     

     

     

     

    353

    Total sales

     

    $

    3,332

     

    $

    2,982

     

    $

    2,724

     

    $

    2,641

     

    $

    11,679

     

     

     

     

     

     

     

     

     

     

     

    (1) Included sales through the March 18, 2024, divestiture.

    Distribution Segment Sales by Product Line

     

    Sales for our Distribution segment by product line were as follows:

     

    2025

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Power generation

     

    $

    1,090

     

    $

    1,200

     

    $

    1,247

     

    $

     

    $

    3,537

    Parts

     

     

    1,031

     

     

    1,015

     

     

    1,013

     

     

     

     

    3,059

    Service

     

     

    416

     

     

    439

     

     

    495

     

     

     

     

    1,350

    Engines

     

     

    370

     

     

    387

     

     

    417

     

     

     

     

    1,174

    Total sales

     

    $

    2,907

     

    $

    3,041

     

    $

    3,172

     

    $

     

    $

    9,120

     

     

     

     

     

     

     

     

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Power generation

     

    $

    707

     

    $

    954

     

    $

    1,091

     

    $

    1,220

     

    $

    3,972

    Parts

     

     

    1,001

     

     

    990

     

     

    1,004

     

     

    985

     

     

    3,980

    Service

     

     

    406

     

     

    448

     

     

    455

     

     

    444

     

     

    1,753

    Engines

     

     

    421

     

     

    437

     

     

    402

     

     

    419

     

     

    1,679

    Total sales

     

    $

    2,535

     

    $

    2,829

     

    $

    2,952

     

    $

    3,068

     

    $

    11,384

    Power Systems Segment Sales by Product Line

     

    Sales for our Power Systems segment by product line were as follows:

     

    2025

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Power generation

     

    $

    1,001

     

    $

    1,205

     

    $

    1,280

     

    $

     

    $

    3,486

    Industrial

     

     

    498

     

     

    506

     

     

    531

     

     

     

     

    1,535

    Generator technologies

     

     

    150

     

     

    178

     

     

    185

     

     

     

     

    513

    Total sales

     

    $

    1,649

     

    $

    1,889

     

    $

    1,996

     

    $

     

    $

    5,534

     

     

     

     

     

     

     

     

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

    In millions

     

    Q1

     

    Q2

     

    Q3

     

    Q4

     

    YTD

    Power generation

     

    $

    853

     

    $

    987

     

    $

    1,055

     

    $

    1,090

     

    $

    3,985

    Industrial

     

     

    420

     

     

    478

     

     

    508

     

     

    526

     

     

    1,932

    Generator technologies

     

     

    116

     

     

    124

     

     

    124

     

     

    127

     

     

    491

    Total sales

     

    $

    1,389

     

    $

    1,589

     

    $

    1,687

     

    $

    1,743

     

    $

    6,408

     

    Cat Lyons

    External Communications

    812-377-0500

    catherine.lyons@cummins.com

    Source: Cummins Inc.

    Continue Reading

  • NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss | AstraZeneca

    NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss | AstraZeneca

    The boss of AstraZeneca has said that unless the UK ramps up spending on new drugs, it could be on a trajectory to only being able to afford cheap, generic medicines rather than cutting-edge treatments.

    Pascal Soriot made the remarks amid an acrimonious standoff between the pharmaceutical industry and the government over drug pricing, which has been blamed for drugmakers pausing or ditching nearly £2bn of investments in the UK this year.

    Britain has been heavily criticised by pharma executives as well as high-profile scientists such as Sir John Bell, for not spending more on medicines, putting it out of line with other countries. Donald Trump has also put pressure on pharma companies to lower their drug prices in the US and increase them elsewhere.

    “To say that countries will only be able to afford generics [drugs] is only an extreme case,” Soriot said on Thursday, stressing that “it’s not the case today of course, but if things continue to deteriorate the way they do … it is actually possible that it happens over time, if the ongoing trend that has been in place for 15-20 years doesn’t change.”

    Soriot noted that the National Institute for Health and Care Excellence (NICE) cost-effectiveness thresholds for new drugs had not changed for two decades, “and we’ve had a lot of inflation in the last five years”.

    Labour has begun drawing up fresh proposals to try to end the drug pricing standoff after intensive talks with the industry and the Trump administration.

    Soriot said that under these proposals, NICE’s cost-effectiveness thresholds would be raised by less than 25%, with an adjustment to get the overall increase to 25%. He called for a substantial adjustment based on … inflation” to these thresholds, plus a “substantial moderation” to the rate at which the government claws back profits of drug sales to the NHS.

    Under a voluntary scheme, drugmakers pay back a chunk of their UK revenues to the government. At the moment, companies repay about a quarter of revenues, compared with rebate rates of 5.7% in France and 7% in Germany. Talks between the industry body and ministers to renegotiate the deal broke down without an agreement in late August.

    The AstraZeneca boss said the government should double spending on new medicines to 0.6% of GDP, from 0.3% now – in line with other countries.

    According to NICE’s thresholds, medicines costing between £20,000 and £30,000 per year of good health gained for patients represent good value for money for the NHS. The Association of the British Pharmaceutical Industry has called for this to be roughly doubled to between £40,000 and £50,000.

    Soriot said these changes are badly needed. “The only thing I can say is what I believe would attract investments in the UK, and really create economic growth on top of improving access for patients.”

    The AstraZeneca boss, who is one of the highest-paid chief executives of UK-listed companies, argued that purchasing cutting-edge treatments would save the NHS money elsewhere, by diagnosing and treating patients early.

    He denied that the company was slowly relocating to the US, but warned that Europe, including the UK, had been losing out to the US and China in terms of introducing new technologies.

    skip past newsletter promotion

    AstraZeneca, Britain’s biggest drugmaker, recently announced that it would list its shares directly on the New York Stock Exchange, in a decision described as a “knock-back for London”. However, it insisted that it would remain headquartered in Cambridge, England, and stay listed on the London Stock Exchange.

    It is one of a number of pharmaceutical companies that have pulled back from UK investments in recent months, ditching the planned £450m expansion of its vaccine facility in Speke in Liverpool at the start of the year, and pausing a new £200m research centre in Cambridge in September.

    At the same time, the firm has announced $50bn of investments in the US, and a deal with the Donald Trump administration to lower its prescription drug prices by up to 80% and sell directly to consumers to cut out costly middlemen. This will stave off threatened US tariffs for three years.

    AstraZeneca said on Thursday it had broken ground on a new $4.5bn manufacturing facility in Virginia, which will create 3,600 jobs and produce the drug substance for its weight management and metabolic portfolio, including its GLP-1 anti-obesity pill that is in intermediate clinical studies.

    It reported an 11% rise in revenues to $43bn for the July to September quarter, with 16% growth in cancer drugs, and made a profit before tax of $3.2bn, up 70%.

    Continue Reading

  • Tonix Pharmaceuticals Holding Corp. (TNXP)

    Tonix Pharmaceuticals Holding Corp. (TNXP)





    CHATHAM, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced that Seth Lederman, M.D., Tonix’s Chief Executive Officer, will be presenting at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 10:00 AM ET.

    Investors interested in arranging a meeting with the Company’s management during the conference should contact their Stifel representative. A webcast of the presentation will be available on the Events page of the Investors section of the Company’s website. A replay of the webcast will be available after the event and will be accessible for 90 days following the event.

    Tonix Pharmaceuticals Holding Corp.*
    Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix has received FDA approval for TonmyaTM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a monoclonal antibody for the seasonal prevention of Lyme Disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

    * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

    This press release and further information about Tonix can be found at www.tonixpharma.com.

    Forward Looking Statements
    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya™ and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Investor Contacts
    Jessica Morris 
    Tonix Pharmaceuticals 
    investor.relations@tonixpharma.com 
    (862) 799-8599 

    Brian Korb 
    astr partners 
    (917) 653-5122 
    brian.korb@astrpartners.com 

    Media Contacts 
    Mary Ann Ondish
    Tonix Pharmaceuticals 
    investor.relations@tonixpharma.com 
    (862) 799-8599 

    Ray Jordan 
    Putnam Insights 
    ray@putnaminsights.com

    INDICATION
    TONMYA is indicated for the treatment of fibromyalgia in adults.
    CONTRAINDICATIONS
    TONMYA is contraindicated:
    In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.
    With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.
    During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.
    In patients with hyperthyroidism.
    WARNINGS AND PRECAUTIONS
    Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.
    Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.
    Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.
    Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.
    CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.
    Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.
    ADVERSE REACTIONS
    The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

    DRUG INTERACTIONS

    MAO inhibitors: Life-threatening interactions may occur.
    Other serotonergic drugs: Serotonin syndrome has been reported.
    CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.
    Tramadol: Seizure risk may be enhanced.
    Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.
    USE IN SPECIFIC POPULATIONS
    Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).
    Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.
    Pediatric use: The safety and effectiveness of TONMYA have not been established.
    Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
    Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.
    Please see additional safety information in the full Prescribing Information.
    To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Source: Tonix Pharmaceuticals Holding Corp.

    Continue Reading

  • Bank of England holds interest rates at 4% ahead of make-or-break budget | Interest rates

    Bank of England holds interest rates at 4% ahead of make-or-break budget | Interest rates

    The Bank of England has kept interest rates on hold at 4% as it warned unemployment was rising and growth remains weak as Rachel Reeves prepares for her make-or-break budget.

    With less than three weeks before the chancellor’s highly anticipated tax and spending measures, the Bank’s monetary policy committee (MPC) voted by a narrow five-four majority to keep borrowing costs unchanged for a second consecutive meeting.

    Holding the casting vote in a finely balanced decision, Andrew Bailey, the Bank’s governor, said that he wanted to “wait and see” whether inflationary pressures in the British economy would continue to fade and if Reeves’s budget would have an impact.

    “We held interest rates at 4% today. We still think rates are on a gradual path downwards, but we need to be sure that inflation is on track to return to our 2% target before we cut them again,” he said.

    Borrowing costs have been cut five times since Labour came to power in July 2024, easing pressure on households and businesses, with the last reduction made in August. Meanwhile, inflation is running at 3.8% – almost twice the Bank’s 2% target.

    In her 26 November fiscal statement the chancellor is expected to increase taxes, potentially slowing the economy, alongside measures taking action against the rising cost of living.

    The decision to hold matched economists expectations, with financial markets putting the odds of a reduction in borrowing costs at below 30%.

    However, the close hold decision and updated gloomy forecasts from the Bank’s policymakers are likely to fuel expectations for a December rate cut after rate setters have had the chance to digest Reeves’s budget.

    Expressing growing concern over the strength of the economy, the Bank said unemployment was on track to climb to a higher peak above 5% early next year amid subdued hiring demand.

    It said inflation was likely to have already peaked at 3.8%, below its previous prediction for an increase to about 4% this autumn, and was set to fall back to about 2.5% next year before returning to its 2% target over the course of 2027.

    Threadneedle Street warned that speculation over Reeves’s budget had probably contributed to weakness in the economy in recent months, and that households had also kept a lid on spending amid heightened pressures on living costs.

    skip past newsletter promotion

    It also found weaker exports to the US and disruption to Britain’s manufacturing base linked to the Jaguar Land Rover cyber-attack had pulled down output in the third quarter, forecasting a weaker growth rate of 0.2%.

    However, policymakers signalled they remained concerned that inflationary pressures could continue to weigh on households and businesses.

    But while most of the MPC said it was a risk that current high rates of inflation might encourage workers and firms to drive up their wage expectations and put up prices, the Bank said the risks were becoming tilted to the downside.

    Signalling readiness to take action in the coming months, Bailey explained in the MPC minutes: “Upside risks to inflation have become less pressing since August, and I see further policy easing to come if disinflation becomes more clearly established in the period ahead.”

    Continue Reading